TechLINKS, January 7, 2003 Collgard Biopharmaceuticals Moves U.S. Headquarters From Boston To Atlanta Collgard Biopharmaceuticals (www.collgard.com) has announced the opening of its new headquarters in Atlanta, Georgia. According to the company's CEO, Dr. Bruce Bach, Collgard intends to maintain its presence in Boston, the location of its original corporate offices, while R&D will continue to operate out of Petach Tikva, Israel where the company was founded. Collgard is a clinical stage biopharmaceutical company currently sponsoring Phase II trials of Tempostatin™ (Halofuginone Hydrobromide), the company's lead agent, which has shown in preclinical model studies to improve tissue response to injury by preventing fibrosis or tissue scar formation. Tissue fibrosis may be triggered by a variety of causes and is thought to play a major role in organ failure (heart, kidney, liver). In laboratory studies Tempostatin™ acts by controlling the speed of the body's natural healing process. By slowing rather than speeding up the response to injury, Tempostatin™ has been shown to markedly improve the outcome of the tissue repair process. "Collgard is moving full speed ahead. The company made enormous scientific and clinical progress in the past year, and we are looking forward to achieving a series of milestone events in year 2003. We are very pleased to be a part of Atlanta's growing biomedical community," said Dr. Bach. Prior to joining Collgard, Dr. Bach was the founder and managing director of MTBC Group, a biotechnology venture-consulting firm located in Atlanta. He has extensive experience in developing and validating biotechnology, having served as the CEO of Lifespex, Inc. and Genetic-X-change, and as a senior executive at Becton, Dickinson. Medica Venture Partners founded Collgard in 1996. Additional investors include Mayo Medical Ventures, Denali Ventures, the Yozma Group, and Comsor. Scientific and clinical collaborators include the Mayo Clinic, the NCI, the EORTC and Harvard Medical School. Collgard was a participant in last fall's highly successful Southeast-Israel Medical Technology Business Exchange (www.usisraelexchange.com) which brought 14 Israeli companies to Atlanta to meet potential strategic partners, investors, and customers, according to AICC chairman Dr. Mark Braunstein (Patient Care Technologies). "We're thrilled that another outstanding Israeli technology company has chosen Atlanta for its U.S. headquarters," he said. Back